Jonathan Knight Kallevang, DO | |
Bldg #50, Farenholt Ave, Agana Heights, GU 96910 | |
(671) 344-9222 | |
Not Available |
Full Name | Jonathan Knight Kallevang |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | Bldg #50, Farenholt Ave, Agana Heights, Guam |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1992200422 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 0102205854 (Virginia) | Primary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Jonathan Knight Kallevang, DO Psc 455 Box 208, Fpo, AP 96540-0003 Ph: (671) 344-9222 | Jonathan Knight Kallevang, DO Bldg #50, Farenholt Ave, Agana Heights, GU 96910 Ph: (671) 344-9222 |
News Archive
Boehringer Ingelheim, one of the world's leading pharmaceutical companies, announced recently the launch of the 'In Reach Africa' program, an initiative aimed at facilitating quality and innovative human and animal healthcare access across the African continent.
A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute.
If quitting smoking is one of your New Year's resolutions, you might want to consider cutting back on your drinking, too.
Following the submission of a 54-page list of complaints by nurses regarding Bathurst hospital, the mayor of the city has called for return to community based hospital boards.
Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
› Verified 4 days ago